Robert Hershberg, a director at Adaptive Biotechnologies Corp ($ADPT), made one open market sale of common shares in the last year, totaling $367 thousand. His most recent transaction occurred on December 10, 2025. These sales rank 7,135th among 11,678 individual insiders, compared to an average of $8.6 million per seller across 6.4 transactions. He recorded no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 4, 2026 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | A | Common Stock | 15625 | $0.00 | 62,347.0000 | 163,162,107 | 33.44% | 0.01% |
| Dec. 10, 2025 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | S | Common Stock | 22968 | $16.00 | 46,722.0000 | 163,162,107 | 32.96% | 0.01% |
| Nov. 5, 2025 | Atai Beckley N.V. | $ATAI | HERSHBERG ROBERT | Not found | A | Stock Option | 456011 | $0.00 | 456,011.0000 | 198,306,455 | 9999.99% | 0.23% |
| Nov. 5, 2025 | Atai Beckley N.V. | $ATAI | HERSHBERG ROBERT | Not found | A | Stock Option | 103000 | $0.00 | 103,000.0000 | 198,306,455 | 9999.99% | 0.05% |
| Nov. 5, 2025 | Atai Beckley N.V. | $ATAI | HERSHBERG ROBERT | Not found | A | Stock Option | 62394 | $0.00 | 62,394.0000 | 198,306,455 | 9999.99% | 0.03% |
| Nov. 5, 2025 | Atai Beckley N.V. | $ATAI | HERSHBERG ROBERT | Not found | A | Stock Option | 97716 | $0.00 | 97,716.0000 | 198,306,455 | 9999.99% | 0.05% |
| Sept. 17, 2025 | HilleVax, Inc. | $HLVX | HERSHBERG ROBERT | President and CEO | U | Common Stock | 1101498 | $0.00 | 0.0000 | 50,141,064 | 100.00% | 2.20% |
| June 18, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | HERSHBERG ROBERT | Director | A | Class A Common Stock | 22016 | $0.00 | 73,732.0000 | 395,072,094 | 42.57% | 0.01% |
| June 18, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | HERSHBERG ROBERT | Director | A | Stock Option (Right to Buy) | 44031 | $0.00 | 44,031.0000 | 395,072,094 | 9999.99% | 0.01% |
| March 12, 2025 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | S | Common Stock | 53000 | $7.59 | 69,690.0000 | 147,101,648 | 43.20% | 0.04% |
| March 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | A | Common Stock | 15394 | $0.00 | 122,690.0000 | 147,101,648 | 14.35% | 0.01% |
| March 4, 2025 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | A | Stock Option (right to buy) | 23726 | $0.00 | 23,726.0000 | 147,101,648 | 9999.99% | 0.02% |
| Feb. 11, 2025 | HilleVax, Inc. | $HLVX | HERSHBERG ROBERT | See Remarks | S | Common Stock | 11901 | $1.76 | 1,101,498.0000 | 0 | 1.07% | 0.00% |
| Feb. 4, 2025 | HilleVax, Inc. | $HLVX | HERSHBERG ROBERT | See Remarks | S | Common Stock | 14634 | $1.89 | 1,113,399.0000 | 0 | 1.30% | 0.00% |
| June 3, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | HERSHBERG ROBERT | Director | A | Class A Common Stock | 13097 | $0.00 | 51,716.0000 | 0 | 33.91% | 0.00% |
| June 3, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | HERSHBERG ROBERT | Director | A | Stock Option (Right to Buy) | 26193 | $0.00 | 26,193.0000 | 0 | 9999.99% | 0.00% |
| March 4, 2024 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | A | Stock Option (right to buy) | 48044 | $0.00 | 48,044.0000 | 144,383,294 | 9999.99% | 0.03% |
| March 4, 2024 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | A | Common Stock | 31328 | $0.00 | 107,296.0000 | 144,383,294 | 41.24% | 0.02% |
| Feb. 8, 2024 | HilleVax, Inc. | $HLVX | HERSHBERG ROBERT | See Remarks | A | Common Stock | 174202 | $0.00 | 1,128,033.0000 | 0 | 18.26% | 0.00% |
| Feb. 8, 2024 | HilleVax, Inc. | $HLVX | HERSHBERG ROBERT | See Remarks | A | Stock Option (Right to Buy) | 226885 | $0.00 | 226,885.0000 | 0 | 9999.99% | 0.00% |
| Feb. 8, 2024 | HilleVax, Inc. | $HLVX | HERSHBERG ROBERT | See Remarks | S | Common Stock | 11597 | $14.93 | 953,831.0000 | 0 | 1.20% | 0.00% |
| June 16, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | HERSHBERG ROBERT | Director | A | Class A Common Stock | 12612 | $0.00 | 38,619.0000 | 0 | 48.49% | 0.00% |
| June 16, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | HERSHBERG ROBERT | Director | A | Stock Option (Right to Buy) | 25224 | $0.00 | 599,014.0000 | 0 | 4.40% | 0.00% |
| June 6, 2023 | FATE THERAPEUTICS INC | $FATE | HERSHBERG ROBERT | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| March 6, 2023 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | A | Stock Option (right to buy) | 23329 | $0.00 | 23,329.0000 | 142,515,917 | 9999.99% | 0.02% |
| March 6, 2023 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | A | Common Stock | 14775 | $0.00 | 75,968.0000 | 142,515,917 | 24.14% | 0.01% |
| Feb. 2, 2023 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | M | Stock Option (Right to Buy) | 53000 | $0.00 | 0.0000 | 142,515,917 | 100.00% | 0.04% |
| Feb. 2, 2023 | Adaptive Biotechnologies Corp | $ADPT | HERSHBERG ROBERT | Director | M | Common Stock | 53000 | $0.45 | 61,193.0000 | 142,515,917 | 646.89% | 0.04% |